Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 33, Badachu Road, Shijingshan District, Beijing, 100144, China.
Aesthetic Plast Surg. 2021 Aug;45(4):1762-1771. doi: 10.1007/s00266-021-02178-7. Epub 2021 Feb 26.
Patients with depressed facial scars complain of their negative effects. However, the efficacy of optional treatment techniques is never completely adequate. This study aimed to assess the efficacy of nanofat injection in the improvement of depressed facial scars.
This retrospective study included patients who underwent depressed facial scar filling with nanofat between November 2017 and January 2020. The FACE-Q scale was sent to patients for feedback regarding satisfaction. Evaluations of the results were also performed by three plastic surgeons.
Among the 52 included patients, 44 patients (29 women and 15 men) completed the questionnaire. Obvious and stable effects were usually acquired 3 months after surgery. Temporary erythema appeared at the injection site to varying degrees, lasting 2 to 3 weeks in 93% of the patients. No other serious postoperative complications were observed in the injection area. The FACE-Q outcomes showed that patients who completed injection therapy more than 1 year prior were significantly more satisfied with the decision to undergo this therapy than those who completed the treatment less than 1 year prior. Furthermore, according to the physicians' evaluations, 91% of patients experienced improvement in scar appearance after treatment.
The low rate of injection-site complications and the safety of this procedure both support the current implementation of nanofat in the treatment of depressed facial scars. The results of the physicians' evaluations and patient satisfaction surveys confirmed the stable effect of nanofat injection in the treatment of depressed facial scars.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
患有凹陷性面部瘢痕的患者会抱怨其负面影响。然而，选择的治疗技术的疗效从未完全充分。本研究旨在评估纳米脂肪注射改善凹陷性面部瘢痕的疗效。
本回顾性研究纳入了 2017 年 11 月至 2020 年 1 月期间接受纳米脂肪填充凹陷性面部瘢痕的患者。患者被发送 FACE-Q 量表以反馈满意度。三位整形医生也对结果进行了评估。
在 52 例纳入的患者中，有 44 例（29 名女性和 15 名男性）完成了问卷调查。术后 3 个月通常会获得明显且稳定的效果。93%的患者注射部位出现不同程度的暂时性红斑，持续 2 至 3 周。在注射部位未观察到其他严重的术后并发症。FACE-Q 结果显示，完成注射治疗 1 年以上的患者对接受这种治疗的决定明显比完成治疗不到 1 年的患者更满意。此外，根据医生的评估，91%的患者在治疗后瘢痕外观得到改善。
注射部位并发症发生率低且该过程安全，这都支持目前将纳米脂肪应用于治疗凹陷性面部瘢痕。医生评估和患者满意度调查的结果证实了纳米脂肪注射治疗凹陷性面部瘢痕的稳定效果。
证据等级 IV：本期刊要求作者为每篇文章指定一个证据等级。如需详细了解这些循证医学等级，请参考目录或在线作者指南www.springer.com/00266。
